Mereo BioPharma Group Past Earnings Performance
Past criteria checks 0/6
Mereo BioPharma Group has been growing earnings at an average annual rate of 32.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 6% per year.
Key information
32.4%
Earnings growth rate
64.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -6.0% |
| Return on equity | -62.5% |
| Net Margin | -4,531.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Revenue & Expenses Breakdown
How Mereo BioPharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -45 | 24 | 16 |
| 30 Jun 24 | 1 | -37 | 23 | 16 |
| 31 Mar 24 | 10 | -26 | 18 | 15 |
| 31 Dec 23 | 10 | -29 | 18 | 16 |
| 30 Sep 23 | 9 | -31 | 23 | 18 |
| 30 Jun 23 | 9 | -32 | 24 | 19 |
| 31 Mar 23 | 0 | -42 | 27 | 24 |
| 31 Dec 22 | 0 | -42 | 26 | 28 |
| 30 Sep 22 | 0 | -31 | 22 | 29 |
| 30 Jun 22 | 0 | -23 | 20 | 33 |
| 31 Mar 22 | 24 | -4 | 21 | 33 |
| 31 Dec 21 | 49 | 17 | 22 | 32 |
| 30 Sep 21 | 49 | -10 | 25 | 28 |
| 30 Jun 21 | 50 | -37 | 30 | 25 |
| 31 Mar 21 | 25 | -131 | 30 | 23 |
| 31 Dec 20 | 0 | -224 | 29 | 22 |
| 30 Sep 20 | 0 | -198 | 25 | 24 |
| 30 Jun 20 | 0 | -177 | 21 | 25 |
| 31 Mar 20 | 0 | -111 | 20 | 27 |
| 31 Dec 19 | 0 | -46 | 21 | 31 |
| 30 Sep 19 | 0 | -41 | 18 | 29 |
| 30 Jun 19 | 0 | -40 | 18 | 30 |
| 31 Mar 19 | 0 | -41 | 17 | 30 |
| 31 Dec 18 | 0 | -41 | 15 | 29 |
| 30 Sep 18 | 0 | -42 | 15 | 30 |
| 30 Jun 18 | 0 | -44 | 14 | 32 |
| 31 Mar 18 | 0 | -50 | 15 | 41 |
| 31 Dec 17 | 0 | -52 | 14 | 47 |
| 30 Sep 17 | 0 | -50 | 14 | 47 |
| 30 Jun 17 | 0 | -47 | 12 | 45 |
| 31 Mar 17 | 0 | -41 | 13 | 37 |
| 31 Dec 16 | 0 | -35 | 14 | 30 |
| 30 Jun 16 | 0 | -39 | 22 | 23 |
Quality Earnings: MREO is currently unprofitable.
Growing Profit Margin: MREO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MREO is unprofitable, but has reduced losses over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare MREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MREO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MREO has a negative Return on Equity (-62.47%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mereo BioPharma Group plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Yun Zhong | BTIG |
| Julian Harrison | BTIG |